MX2021007815A - Derivados de n-(4-(oxazol-5-il)fenil)cromano-3-carboxamida y compuestos relacionados a manera de estimuladores de la producción de células precursoras de la retina para el tratamiento contra enfermedades neurorretinianas. - Google Patents

Derivados de n-(4-(oxazol-5-il)fenil)cromano-3-carboxamida y compuestos relacionados a manera de estimuladores de la producción de células precursoras de la retina para el tratamiento contra enfermedades neurorretinianas.

Info

Publication number
MX2021007815A
MX2021007815A MX2021007815A MX2021007815A MX2021007815A MX 2021007815 A MX2021007815 A MX 2021007815A MX 2021007815 A MX2021007815 A MX 2021007815A MX 2021007815 A MX2021007815 A MX 2021007815A MX 2021007815 A MX2021007815 A MX 2021007815A
Authority
MX
Mexico
Prior art keywords
sub
sup
vii
iii
group
Prior art date
Application number
MX2021007815A
Other languages
English (en)
Inventor
Mauro Marigo
Matthias Steger
Alex Mueller
Bernhard Fasching
Daphna Mokady
Original Assignee
Endogena Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endogena Therapeutics Inc filed Critical Endogena Therapeutics Inc
Publication of MX2021007815A publication Critical patent/MX2021007815A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen nuevos compuestos y a un método para tratar una enfermedad de la retina que conlleva a la pérdida de fotorreceptores o degeneración de retina externa, que comprende que sea administrable el compuesto de la fórmula (I) (ver Fórmula) (I) o una sal farmacéuticamente aceptable, una mezcla racémica, un enantiómero correspondiente o, si corresponde, un diastereómero correspondiente del mismo, en donde: A se selecciona a partir del grupo que consiste en un 5-oxazolilo, un piridin-4-ilo, un triazolilo, un oxadiazolilo, un imidazolilo y un residuo 2-metiloxazol-5-ilo, R1 y R12 se seleccionan indistintamente a partir del grupo que consiste en hidrógeno, fluoro, cloro, metoxilo, trifluorometilo, metilo y difluorometoxilo, B se selecciona a partir del grupo que consiste en un residuo de la fórmula (II), (III), (IV), (V), (VI), (VII), (VIII) y (IX) (ver Fórmulas) en donde, "*" denota el punto de unión al resto de la molécula. R2, R3, R4, R5, R2I, R3I, R4I, R5I, R2II, R3II, R4II, R5II, R2III, R3III, R4III, R5III, R2IV, R3IV, R4IV, R5IV, R2V, R3V, R4V, R5V, R2VI, R3VI, R4VI, R5VI, R2VII, R3VII, R4VII, y R5VII se seleccionan indistintamente a partir del grupo que consiste en hidrógeno, un alquilo lineal o ramificado que tiene 1 a 3 átomos de carbono, fluoro, cloro, bromo, metoxilo, etoxilo, propoxilo, 2,2,2-trifluorometilo y difluorometoxilo.
MX2021007815A 2018-12-28 2019-12-27 Derivados de n-(4-(oxazol-5-il)fenil)cromano-3-carboxamida y compuestos relacionados a manera de estimuladores de la producción de células precursoras de la retina para el tratamiento contra enfermedades neurorretinianas. MX2021007815A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/235,429 US10807973B2 (en) 2018-12-28 2018-12-28 Compounds for use as therapeutically active substances in the treatment of retinal diseases
PCT/US2019/068768 WO2020140050A1 (en) 2018-12-28 2019-12-27 N-(4-(oxazol-5-yl)phenyl)chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases

Publications (1)

Publication Number Publication Date
MX2021007815A true MX2021007815A (es) 2021-10-01

Family

ID=69191293

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007815A MX2021007815A (es) 2018-12-28 2019-12-27 Derivados de n-(4-(oxazol-5-il)fenil)cromano-3-carboxamida y compuestos relacionados a manera de estimuladores de la producción de células precursoras de la retina para el tratamiento contra enfermedades neurorretinianas.

Country Status (15)

Country Link
US (2) US10807973B2 (es)
EP (1) EP3902798B1 (es)
JP (1) JP7492964B2 (es)
KR (1) KR20210110652A (es)
CN (1) CN113227086A (es)
AU (1) AU2019413682B2 (es)
BR (1) BR112021011633A2 (es)
CA (1) CA3125327A1 (es)
CL (1) CL2021001698A1 (es)
EA (1) EA202191075A1 (es)
IL (1) IL284302A (es)
MX (1) MX2021007815A (es)
PH (1) PH12021551133A1 (es)
SG (1) SG11202105229TA (es)
WO (1) WO2020140050A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299160A (en) * 2020-06-19 2023-02-01 Endogena Therapeutics Inc New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium
US11541039B2 (en) * 2020-10-08 2023-01-03 Endogena Therapeutics, Inc. Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epithelium

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2216439A1 (en) 1996-09-25 1998-03-25 Derek Van Der Kooy Pharmaceuticals containing retinal stem cells
CA2339123A1 (en) 1998-07-31 2000-02-10 Nippon Soda Co., Ltd. Phenylazole compounds, process for producing the same and drugs for hyperlipemia
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
JP5575646B2 (ja) 2007-08-27 2014-08-20 アボット ゲーエムベーハー ウント カンパニー カーゲー ４−（４−ピリジニル）−ベンズアミドおよびｒｏｃｋ活性調節因子としてのこれらの使用
MX2010006046A (es) * 2007-12-13 2010-06-23 Amgen Inc Moduladores de gamma secretasa.
EP2234618A4 (en) 2007-12-21 2011-04-27 Scripps Research Inst BENZOPYRANE AND ANALOGUE AS RHO KINASE INHIBITORS
US9018202B2 (en) * 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
US20130046003A1 (en) 2011-07-22 2013-02-21 Mohammed I. Dibas Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases
WO2014079850A1 (en) 2012-11-23 2014-05-30 F. Hoffmann-La Roche Ag Substituted heterocyclic derivatives
DE102013110714A1 (de) 2013-09-27 2015-04-02 Eberhard Karls Universität Tübingen Medizinische Fakultät Prophylaxe und Behandlung einer nicht auf einer Proteinfaltungsstörung beruhenden neurodegenerativen Erkrankung
US9617214B2 (en) * 2013-11-08 2017-04-11 The Translational Genomics Research Institute Compounds for cognitive enhancement and methods of use thereof
WO2016073931A1 (en) 2014-11-07 2016-05-12 The Johns Hopkins University Treatment of retinitis pigmentosa with n-acetylcysteine amide
WO2016195833A1 (en) 2015-05-29 2016-12-08 Edge Therapeutics, Inc. Compositions and methods for reducing visual loss

Also Published As

Publication number Publication date
SG11202105229TA (en) 2021-07-29
EA202191075A1 (ru) 2021-10-06
KR20210110652A (ko) 2021-09-08
EP3902798B1 (en) 2023-12-20
US10807973B2 (en) 2020-10-20
BR112021011633A2 (pt) 2021-09-08
JP7492964B2 (ja) 2024-05-30
WO2020140050A1 (en) 2020-07-02
CN113227086A (zh) 2021-08-06
CL2021001698A1 (es) 2021-12-17
PH12021551133A1 (en) 2022-02-21
AU2019413682B2 (en) 2023-11-23
US20220089583A1 (en) 2022-03-24
IL284302A (en) 2021-08-31
CA3125327A1 (en) 2020-07-02
AU2019413682A1 (en) 2021-06-03
US20200207749A1 (en) 2020-07-02
JP2022516087A (ja) 2022-02-24
EP3902798A1 (en) 2021-11-03
EP3902798C0 (en) 2023-12-20

Similar Documents

Publication Publication Date Title
JP5039564B2 (ja) 鎮痛薬としての１−ベンジル−１−ヒドロキシ−２，３−ジアミノ−プロピルアミン、３−ベンジル−３−ヒドロキシ−２−アミノ−プロピオン酸アミドおよび関連化合物の使用方法
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
PH12021551133A1 (en) N-(4-(oxazol-5-yl)phenyl)chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases
JP4805164B2 (ja) 殺寄生虫剤としての置換アリールピラゾール類
RU2007142328A (ru) Производные тиоксантина в качестве ингибиторов миелопероксидазы
MA31924B1 (fr) Derives d'oxadiazole actifs sur la sphingosine-1-phosphate (s1p)
PT828703E (pt) Sintese assimetrica de (-) 6-cloro-4-ciclopropil-etinil-4-trifluorometil-1,4-dihidro-2h-3,1-benzoxazin-2-ona
RU2005111975A (ru) Производные фенэтаноламина для лечения респираторных заболеваний
HUP0400992A2 (hu) Karbonsavval helyettesített oxazol-származékok, eljárás előállításukra és PPAR-alfa- és -gamma-aktivátorként való alkalmazásuk diabétesz kezelésére felhasználható gyógyszerek készítésére
TW200519092A (en) Malonamide derivatives
RU2014149183A (ru) Проницаемые ингибиторы гликозидазы и их применения
RU2012137501A (ru) Сигма-лиганды для применения при профилактике и/или лечении послеоперационной боли
TNSN07014A1 (en) New heterocyclic carboxylic acid amide derivatives
EA200700103A1 (ru) НОВЫЕ 2-ЗАМЕЩЁННЫЕ D-ГОМО-ЭСТРА-1,3,5(10)-ТРИЕНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 17β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ ТИПА 1
MA35133B1 (fr) Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5
JP2013525262A5 (es)
JP2013513615A (ja) 脂肪酸アミドヒドロラーゼのアゾ環状阻害薬
EA201690408A1 (ru) Производные этинила
MA31674B1 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
EA009193B1 (ru) N-арилсульфонил-3-аминоалкоксииндолы
RU2004139041A (ru) Применение гетероаренкарбоксамидов в качестве дофамин-d3 лигандов для лечения заболеваний центральной нервной системы
RU2008129623A (ru) Ингибиторы ccr9 активности
JP7488396B2 (ja) 新規の芳香族化合物
RU2695383C2 (ru) Производные бендамустина, родственные соединения и их медицинское применение для лечения рака
RU2013113301A (ru) Замещенные 2-оксо- и 2-тиоксо-дигидрохинолин-3-карбоксамиды в качестве модуляторов kcnq2/3